Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis - Full Text View

Purpose

This is a multicenter clinical trial, phase III, non-inferiority, controlled by active medicine, open, randomized, enroll 538 children, 2 to 12 years old, with acute inflammation upper airway, characterized by nasal congestion and runny nose, lasting at least 24 hours and a maximum of 48 hours prior to inclusion. The subjects will be allocated in 2 parallel groups, and will receive the medicines of study, according of the randomization.

Condition	Intervention	Phase
Nasal Congestion and Inflammations Rhinitis	Drug: brompheniramine + phenylephrine Drug: Brompheniramine + pseudoephedrine	Phase 3

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Multicenter Clinical Trial, Phase III, Randomized, Open, Parallel Group, Comparative for Evaluate the Efficacy and Safety of Fixed Dose Combinations of Brompheniramine Maleate + Phenylephrine Chlorhydrate in Different Dosage Forms Versus Fixed Dose Combination of Reference for the Treatment of Nasal Congestion and Runny Nose Present in Acute Crisis of Viral Rhinitis (Common Cold) and Allergic Reactions, in Patients From 2 to 12 Years Old

Resource links provided by NLM:

MedlinePlus related topics: Common Cold

Drug Information available for: Phenylephrine Phenylephrine hydrochloride Pseudoephedrine Brompheniramine maleate Oxymetazoline Oxymetazoline hydrochloride

U.S. FDA Resources

Further study details as provided by Ache Laboratorios Farmaceuticos S.A.:

Primary Outcome Measures:

Improvement of nasal congestion and runny nose, after 48 hours of treatment [ Time Frame: 48 hours after single dose of double-blind treatment ] [ Designated as safety issue: No ]
Improvement is defined as a reduction of at least one point on the rating scale, in both nasal symptoms, after 48 hours of treatment.

Participants were evaluated (self-assessment) for pain intensity by using a 4-point rating scale: 0=none, 1=mild, 2=moderate, and 3=severe.

Secondary Outcome Measures:

Overall score of nasal and extranasal symptoms (nasal congestion, runny nose, sneezing, watery eyes and itching) [ Time Frame: After 2 and 5 (± 1) days of treatment ] [ Designated as safety issue: No ]
Clinical score of upper airway compromise [ Time Frame: After 2 and 5 (± 1) days of treatment ] [ Designated as safety issue: No ]
Proportion of subjects who used at least once the rescue medication [ Time Frame: Within 2 days and the period of 5 (± 1) days of treatment ] [ Designated as safety issue: No ]
Safety descriptive about occurence of adverse events, evaluation of results of general physical examination. [ Time Frame: Will be evaluated during the 5(± 1) days of treatment ] [ Designated as safety issue: Yes ]
Collection of safety data throughout the whole study period

Estimated Enrollment:	538
Study Start Date:	September 2011
Estimated Primary Completion Date:	March 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Group 1 Fixed dose combination of brompheniramine + phenylephrine	Drug: brompheniramine + phenylephrine Oral solution: brompheniramine (2mg/mL) and phenylephrine (2,5 mg/mL), t.i.d., according weight of patient. OR Syrup: brompheniramine (2mg/5mL) and phenylephrine(5 mg/5mL), t.i.d., according weight of patient.
Active Comparator: Group 2 Fixed dose combination of brompheniramine + pseudoephedrine	Drug: Brompheniramine + pseudoephedrine Elixir: Brompheniramine (0,2mg/mL) and pseudoephedrine (3,0 mg/mL), t.i.d., according weight of patient

Eligibility

Ages Eligible for Study:	2 Years to 12 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients between 2 and 12 years old, of both sexes. Must be responsible be able to understand and provide ICF and able to allow compliance to treatment and protocol requirements, fulfilling the regular visits;
Patients with symptoms of acute inflammation upper airway, starting between 24 and 48 hours of their inclusion in this study protocol;
Presence of runny nose classification moderate or severe (score 2 or 3), according the responsible evaluation;
Presence of nasal congestion classification moderate or severe (score 2 or 3), according the responsible evaluation.

Exclusion Criteria:

Patients younger than 2 years or percentile for body weight and/or height less than 25;
History of nasal obstruction in chronic rhinosinusitis and / or nasal polyposis;
Oral chronic respirator with history for six months;
Personal history of nasal surgery that in the opinion of the investigator can influence the resistance to nasal airflow;
Patients who have a clinical history confirmed (diagnosed) with asthma;
Patients under medicine treatment for chronic allergy;
Patients with gastroesophageal reflux disease;
Presence of psychiatric illness of any kind;
Presence of mental retardation from any cause;
Diagnosis of renal or hepatic failure;
Patients with genetic syndromes;
History of hypersensitivity to (s) drug (s) of study or their excipients;
Use of prohibited medicine within the prescribed period before the V0 - Inclusion Visit (Table 1);
Patients who participated in the last 12 months, of clinical trials protocols;
Patients who didn´t updated vaccine book;
Relatives of sponsor´s or study site´s employee;
Suggestive signs of bacterial infection of upper airways at rhinoscopy, otoscopy or oroscopy;
Presence of anemic/inflamed turbinate at anterior rhinoscopy;
Presence of septal deviation grade II and III (in any region and any nasal cavity) and / or nasal polyps, or other conditions determinants of nasal obstruction;
Presence of purulent or mucopurulent secretion, nasal vault or mal formations (cleft lip or cleft nasolabial corrected or not) in nasal vestibule;
Current evidence of clinically significant diseases: hematopoietic, gastrointestinal, cardiovascular, hepatic, renal, neurological, endocrine, psychiatric, autoimmune, pulmonary, or another disease that block the patient participation;
Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the patient or interfere with the endpoints of study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01393548

Sponsors and Collaborators

Ache Laboratorios Farmaceuticos S.A.

Investigators

Principal Investigator:

Fábio M Castro

IMA

More Information

No publications provided

Responsible Party:	Ache Laboratorios Farmaceuticos S.A.
ClinicalTrials.gov Identifier:	NCT01393548 History of Changes
Other Study ID Numbers:	ACH-DCN-03(03/10)
Study First Received:	October 27, 2010
Last Updated:	July 12, 2011
Health Authority:	Brazil: Ethics Committee Brazil: Ministry of Health

Keywords provided by Ache Laboratorios Farmaceuticos S.A.:

Rhinitis
common cold
nasal symptoms
children

Additional relevant MeSH terms:

Inflammation
Rhinitis
Pathologic Processes
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Brompheniramine
Ephedrine
Phenylephrine
Oxymetazoline
Pseudoephedrine
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Anti-Allergic Agents
Therapeutic Uses
Nasal Decongestants
Vasoconstrictor Agents
Cardiovascular Agents
Respiratory System Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Central Nervous System Stimulants

ClinicalTrials.gov processed this record on May 16, 2013